ORTIKOS (budesonide ER)

Self-Administration – oral

Diagnosis considered for coverage:
  • Treatment of Mild to Moderate Active Crohn's Disease
    • Indicated for the treatment of mild to moderate active Crohn's disease involving the ileum and/or the ascending colon in patients 8 years of age and older
  • Maintenance of Clinical Remission of Mild to Moderate Crohn's Disease
    • Indicated for the maintenance of clinical remission of mild to moderate Crohn's disease involving the ileum and/or the ascending colon for up to 3 months in adults
Coverage Criteria:

For diagnosis of treatment of active Crohn's Disease:

  • Dose does not exceed the maximum FDA approved dose for age
    • Adults: 9 mg once daily for up to 8 weeks
    • Pediatric patients 8 to 17 years who weigh more than 25 kg: 9 mg once daily for up to 8 weeks, followed by 6 mg once daily for 2 weeks; AND
  • Patient is 8 years of age and older; AND
  • Chart notes document a medical reason why generic budesonide delayed-release 3 mg capsules cannot be used

For diagnosis of maintenance of remission of Crohn's Disease:

  • Dose does not exceed 6 mg once daily; AND
  • Patient is 18 years of age and older; AND
  • Patient has completed an 8-week course of Ortikos 9mg once daily for Crohn’s disease and is currently in remission
Reauthorization Criteria:

For diagnosis of treatment of active Crohn's Disease:

  • Dose does not exceed 9 mg once daily for up to 8 weeks; AND
  • Patient is 18 years of age and older; AND
  • Medical records confirm patient had a recurring episode of active disease
Coverage Duration: 

For diagnosis of treatment of active Crohn's Disease:

  • Initial:
    • Adults: 8 weeks
    • Pediatric patients:10 weeks
  • Reauthorization:
    • 8 weeks

For diagnosis of maintenance of remission of Crohn's Disease:

  • 3 months
Authorization is not covered for the following:

The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.

Additional Information: 
  • Recommended Dose for Treatment of Mild to Moderate Active Crohn's Disease:
    • Adults: 9 mg orally once daily for up to 8 weeks. Repeated 8 week courses of Ortikos can be given for recurring episodes of active disease
    • Pediatric patients 8 to 17 years who weigh more than 25 kg: 9 mg orally once daily for up to 8 weeks, followed by 6 mg once daily for 2 weeks
  • Recommended Dose for Maintenance of Clinical Remission of Mild to Moderate Crohn's Disease:
    • 6 mg orally once daily for maintenance of clinical remission up to 3 months
    • For maintenance of clinical remission of mild to moderate Crohn’s disease, continued treatment with Ortikos 6 mg for more than 3 months has not been shown to provide substantial clinical benefit
  • Avoid use with CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, erythromycin, and cyclosporine)
Policy Updates:
  • 8/30/2022 – New policy approved by P&T
References:
  • Ortikos Prescribing Information. Ferring Pharmaceuticals Inc. Parsippany, NJ. October 2019.

Last review date: August 30, 2022

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone